
    
      This study was to evaluate the safety, tolerability,efficacy, pharmacokinetics and
      immunogenicity of recombinant human albumin injection in Patients With Hepatic Cirrhosis. The
      study design consists of two phases: Screening and treatment phase(dose increasing
      stage).Following the Screening phase, all eligible subjects will be randomized to receive
      recombinant human albumin injection or HumanAlbumin, study medication in a 3:1 ratio.Dose
      increasing stage (including 3 dose groups with increasing dose, and each group was set with
      HumanAlbumin control).The initial dose was 10g. The highest dose group was set at 30g.
    
  